Cariprazine — Membership Pricing

Other medications in Mental Health

• Chlordiazepoxide
• Chlorpromazine
• Citalopram
• Clomipramine
• Clonazepam
• Clonidine
• Clorazepate
• Clozapine

About Cariprazine

Cariprazine is a medication prescribed for several serious psychiatric conditions, offering a path to improved mental well-being for many. Understanding its role and potential costs is crucial. At TheDrugClub, we're dedicated to helping our members access essential medications like cariprazine more affordably, reducing the financial burden of managing complex conditions.

Cariprazine, an atypical antipsychotic medication, is a vital treatment option for individuals grappling with specific mental health disorders. It is primarily approved for the acute and maintenance treatment of schizophrenia, the acute treatment of manic or mixed episodes associated with bipolar I disorder, and the treatment of bipolar depression. Additionally, it can be prescribed as an adjunctive therapy to antidepressants for adults with major depressive disorder (MDD) who have not responded adequately to antidepressant monotherapy. Its broad utility makes it a significant tool in managing complex psychiatric symptoms, helping patients achieve greater stability and improved quality of life.

So, how does cariprazine work its therapeutic magic? Unlike some older antipsychotics, cariprazine acts as a partial agonist at dopamine D2 and D3 receptors, with a preferential binding to D3 receptors. It also functions as a partial agonist at serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. By modulating these critical neurotransmitter systems, cariprazine helps to restore balance in the brain. This complex mechanism is thought to contribute to its effectiveness in reducing symptoms like hallucinations, delusions, mood swings, and severe depressive episodes, without causing some of the more severe side effects associated with earlier generations of antipsychotics.

For many, the biggest hurdle to consistent treatment is cost. Cariprazine is a specialty medication, and its price can be substantial. Without insurance, a month's supply can typically range from several hundred to over a thousand dollars, depending on the dosage and pharmacy. This high cost often places a significant financial strain on patients and their families, making adherence to treatment challenging. Finding ways to mitigate these expenses is paramount for ensuring continuous care.

This is where TheDrugClub steps in to support its members. We understand the financial pressures of managing chronic conditions. Members of TheDrugClub may access significant savings on medications

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Cariprazine is approved for (FDA label)

VRAYLAR ® is indicated for: • Treatment of schizophrenia in adult and pediatric patients 13 years of age and older [see Clinical Studies ( 14.1 )] • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older [see Clinical Studies ( 14.2 )] • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients [see Clinical Studies ( 14.3 )] • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients [see Clinical Studies ( 14.4 )] VRAYLAR is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults and pediatric patients 13 years of age and older ( 1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients 10 years of age and older ( 1 ) Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1 ) Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 18, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Cariprazine (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.2 )] . WARNING : INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 ) Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. ( 5.2 )

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cariprazine (FDA label)

VRAYLAR (cariprazine) capsules are available in six strengths. 0.5 mg capsules: Ivory to yellow cap and a grey to green body imprinted with “FL 0.5” 0.75 mg capsules: Grey to green cap and blue body imprinted with “FL 0.75” 1.5 mg capsules: White cap and body imprinted with “FL 1.5” 3 mg capsules: Green to blue-green cap and white body imprinted with “FL 3” 4.5 mg capsules: Green to blue-green cap and body imprinted with “FL 4.5” 6 mg capsules: Purple cap and white body imprinted with “FL 6” Capsules: 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cariprazine (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Suicidal Thoughts and Behaviors [see Boxed Warning and Warnings and Precautions ( 5.2 )] Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions ( 5.3 )] Neuroleptic Malignant Syndrome [see Warnings and Precautions ( 5.4 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.5 )] Late Occurring Adverse Reactions [see Warnings and Precautions ( 5.6 )] Metabolic Changes [see Warnings and Precautions ( 5.7 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.8 )] Orthostatic Hypotension and Syncope [see Warnings and Precautions ( 5.9 )] Falls [see Warnings and Precautions ( 5.10 )] Seizures [ see Warnings and Precautions ( 5.11 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.12 )] Body Temperature Dysregulation [see Warnings and Precautions ( 5.13 )] Dysphagia [see Warnings and Precautions ( 5.14 )] Most common adverse reactions in adults (incidence ≥ 5% and at least twice the rate of placebo) were ( 6.1 ) : Schizophrenia: extrapyramidal symptoms and akathisia Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness Bipolar depression: nausea, akathisia, restlessness, and extrapyramidal symptoms Adjunctive treatment of MDD: akathisia, restlessness, fatigue, constipation, nausea, insomnia, increased appetite, dizziness, and extrapyramidal symptoms To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cariprazine (FDA label)

VRAYLAR is contraindicated in patients with history of a hypersensitivity reaction to cariprazine. Reactions have ranged from rash, pruritus, urticaria, and reactions suggestive of angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, and swelling face). Known hypersensitivity to VRAYLAR ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cariprazine (FDA label)

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack) ( 5.3 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring ( 5.4 ) Tardive Dyskinesia : Discontinue if appropriate ( 5.5 ) Late-Occurring Adverse Reactions: Because of VRAYLAR’s long half-life, monitor for adverse reactions and patient response for several weeks after starting VRAYLAR and with each dosage change ( 5.6 ) Metabolic Changes : Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis : Perform complete blood counts (CBC) in patients with pre-existing low white blood cell counts (WBC) or history of leukopenia or neutropenia.

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Cariprazine (FDA label)

Table 15 displays clinically significant drug interactions with VRAYLAR. Table 15. Clinically Significant Drug Interactions with VRAYLAR Strong or Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of VRAYLAR with a strong or moderate CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone [see Clinical Pharmacology ( 12.3 ) ]. Intervention: If VRAYLAR is used with a strong or moderate CYP3A4 inhibitor, reduce VRAYLAR dosage [see D osage and A dministration ( 2.6 ) ] . CYP3A4 Inducers Clinical Impact: CYP3A4 is responsible for the formation and elimination of the active metabolites of cariprazine.

Source: FDA prescribing information (DailyMed). Set ID: 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f. SPL document ID: ef3db4f6-9b04-4ffe-b72e-7ab3ceccb224. Label effective date: December 18, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.